A detailed history of Rangeley Capital, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Rangeley Capital, LLC holds 10,000 shares of LYEL stock, worth $4,000. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,000
Holding current value
$4,000
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$0.48 - $0.74 $4,800 - $7,400
10,000 New
10,000 $5.38 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $99.1M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Rangeley Capital, LLC Portfolio

Follow Rangeley Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rangeley Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rangeley Capital, LLC with notifications on news.